Effect of tyrosine kinase inhibitors on male fertility in patients with chronic phase chronic myeloid leukemia
George Nesr, Simone Claudiani, Dragana Milojković, Andrew J. Innes, Fiona Fernando, Irene Caballes, Patience Mungozi, Richard Szydlo, Silvia Lovato, Channa Jayasena, Jane F. Apperley
Abstract
Advancements in the management of patients with chronic myeloid leukemia (CML) allowed them to achieve survival comparable with their healthy counterparts. Consequently, their care has widened with growing focus on quality of life, including parenting children. Although tyrosine kinase inhibitors (TKI) are contraindicated in pregnancy given their teratogenic effect, their effect on male fertility is less clear with contradictory results from animal studies and case reports/series. We compared the sperm analysis parameters, as the gold-standard assessment for male fertility, of 11 patients with CP- CML before and after TKI therapy. Median therapy duration was 5.1 years (range: 2.5–16.5). The sperm concentration, % progressive, and total motility before and after therapy were not significantly different (p = 0.376, 0.569, and 0.595, respectively). Our results suggest no impairment in fertility potential in male patients after TKI therapy. A larger sample size is crucial to support/refute our findings.